Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Tag: GH/IGF-1

  • What Does the Published Research Say About CJC-1295 Without DAC?

    Research Context

    This synthesis isolates what the included literature shows—and does not show—about CJC-1295 without DAC. The packet contains: two human study sources (a pharmacodynamic study in healthy adults and a human biomarker study; plus a clinical trial registry entry in a disease-specific context), one netnographic review source, and three preclinical/analytical sources. Importantly, the direct human data provided (e.g., [pubmed:16352683], [pubmed:19386527]) describe a long-acting CJC-1295 GHRH analog; these should not be treated as interchangeable with a non-DAC variant.

    Key Takeaway

    Most direct human findings in this packet concern a long-acting CJC-1295 formulation, not a non-DAC variant. Evidence shows GH/IGF-1 biomarker changes and lists a disease-specific trial, but no human outcome data specific to a non-DAC variant are included.

    Direct Answer

    Published research in this packet shows that a long-acting CJC-1295 GHRH analog can prolong GH and IGF-1 secretion in healthy adults and alter serum protein profiles (biomarker-level findings) [pubmed:16352683][pubmed:19386527]. A clinical trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, but no peer-reviewed outcomes are provided here [clinicaltrials:NCT00267527]. Netnographic review literature documents non-medical use narratives [pubmed:26771670]. Analytical studies in equine matrices describe detection methods, not therapeutic effects [pubmed:30938069][pubmed:30489688]. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant.

    —

    Direct Human Evidence

    • Pharmacodynamic study (healthy adults): A long-acting CJC-1295 GHRH analog produced prolonged stimulation of GH and IGF-1 secretion. Context noted that native GHRH has short duration, motivating evaluation of longer-acting analogs [pubmed:16352683].
    • Human biomarker/mechanistic study (normal adults): Activation of the GH/IGF-1 axis by CJC-1295 (long-acting GHRH analog) was associated with changes in serum protein profiles. This is biomarker-level/mechanistic evidence and not controlled clinical outcome data [pubmed:19386527].
    • Disease-specific clinical trial registry entry: A study was registered to evaluate CJC-1295 in HIV patients with visceral obesity; the packet does not provide peer-reviewed outcomes from this trial [clinicaltrials:NCT00267527].

    Variant alignment clarification: The human studies above pertain to a long-acting CJC-1295 formulation. Given this article’s focus on “CJC-1295 without DAC,” these data should not be used as stand-in evidence for a non-DAC variant.

    —

    Review and Observational Context

    • Netnography of female use narratives: Documents online “folk pharmacology” describing interests such as muscle enhancement, fat loss, and skin appearance related to CJC-1295. This frames context but does not constitute primary human outcome evidence [pubmed:26771670].

    —

    Preclinical, Mechanistic, and Analytical Evidence

    • Analytical method development (equine plasma):
    • LC–MS/MS method to confirm CJC-1295 in equine plasma [pubmed:30938069].
    • Immuno-PCR screening for GHRH analogs in equine plasma [pubmed:30489688].

    These are analytical/anti-doping methods, not therapeutic or outcome studies.

    • Human biomarker/mechanistic example (for clarity, still human, not outcomes): Serum protein profile changes consistent with GH/IGF-1 axis activation following exposure to a long-acting GHRH analog [pubmed:19386527]. This informs mechanism/biomarkers but not clinical efficacy.

    These findings should not be presented as established human therapeutic outcomes.

    —

    What Is Not Established

    • No direct human outcome data specific to a non-DAC CJC-1295 variant are included in this packet.
    • Dosing and general safety across off-label or non-study populations are not addressed here.
    • Biomarker changes (GH/IGF-1, serum protein profiles) do not establish clinical benefit [pubmed:16352683][pubmed:19386527].
    • Extrapolation from a disease-specific registry entry (HIV-associated visceral obesity) to broader populations or indications is not supported without published outcomes [clinicaltrials:NCT00267527].
    • Analytical method papers in equine models are not evidence of therapeutic effects [pubmed:30938069][pubmed:30489688].

    —

    Conclusion

    Within this packet, human evidence centers on long-acting CJC-1295 analogs that modulate GH/IGF-1 and associated biomarkers, plus a trial registered in a specific disease context without outcomes provided. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant, and they do not support generalized wellness, aesthetic, or performance claims.

    —

    FAQ

    • Does this packet include human outcome data for a non-DAC CJC-1295 variant?
    • No. The human evidence provided pertains to a long-acting formulation; no direct human outcome data specific to a non-DAC variant are included.
    • What human findings are reported for CJC-1295 in this packet?
    • Prolonged GH and IGF-1 secretion in healthy adults and serum protein profile changes consistent with GH/IGF-1 axis activation—both biomarker-level findings, not demonstrated clinical outcomes [pubmed:16352683][pubmed:19386527].
    • Is there a disease-specific clinical trial?
    • A study in HIV-associated visceral obesity is registered, but this packet does not include peer-reviewed outcome data from that trial [clinicaltrials:NCT00267527].
    • Do the equine detection studies inform therapeutic effects in humans?
    • No. They describe analytical methods for detecting CJC-1295 or related analogs in equine plasma, not therapeutic outcomes [pubmed:30938069][pubmed:30489688].
    • Can biomarker changes be interpreted as proof of benefit?
    • No. Mechanistic/biomarker signals (e.g., GH/IGF-1 increases, serum protein shifts) do not establish clinical efficacy [pubmed:16352683][pubmed:19386527].

    —

    References

    • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/ [pubmed:16352683]
    • Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. https://pubmed.ncbi.nlm.nih.gov/26771670/ [pubmed:26771670]
    • A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. https://pubmed.ncbi.nlm.nih.gov/30938069/ [pubmed:30938069]
    • An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. https://pubmed.ncbi.nlm.nih.gov/30489688/ [pubmed:30489688]
    • Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/ [pubmed:19386527]
    • A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. https://clinicaltrials.gov/study/NCT00267527 [clinicaltrials:NCT00267527]
    • PubChem compound record: CJC 1295. https://pubchem.ncbi.nlm.nih.gov/compound/91971820 [pubchem:91971820]
    • Google Patents search for CJC-1295. https://patents.google.com/?q=CJC-1295 [patent_search:cjc-1295]